Fluticasone propionate 100 powder

Initial dose should be based upon previous therapy and asthma severity; consideration should be given to current control of asthma symptoms and risk of future exacerbations:

4 to 11 years:

Fluticasone propionate INHALATION POWDER (Flovent Diskus[R]):
Patients new to ICS: Initial dose: 50 mcg via oral inhalation twice a day
-Patients previously receiving ICS as well as patients who have not adequately responded after 2 weeks may be titrated to a higher dose
Maximum dose: 100 mcg twice a day
Fluticasone propionate INHALATION AEROSOL (Flovent HFA[R]):
88 mcg via oral inhalation twice a day
Maximum dose: 88 mcg twice a day

12 years or older:

Fluticasone propionate INHALATION AEROSOL (Flovent HFA[R]):
Patients new to ICS: Initial dose: 88 mcg via oral inhalation twice a day
-Patients previously receiving ICS as well as patients who have not adequately responded after 2 weeks may be titrated to a higher dose
Maximum Dose: 880 mcg twice a day

Fluticasone propionate INHALATION POWDER (Flovent Diskus[R]):
Patients new to ICS: Initial dose: 100 mcg via oral inhalation twice a day
-Patients previously receiving ICS as well as patients who have not adequately responded after 2 weeks may be titrated to a higher dose
Maximum dose: 1000 mcg twice a day

Fluticasone propionate INHALATION POWDER (Armonair Respiclick[R]): One oral inhalation twice a day
-Initial dose for patients new to ICS: 55 mcg (low dose) via oral inhalation twice a day
-Patients previously receiving ICS as well as patients who have not adequately responded after 2 weeks may be titrated to a higher dose of 113 mcg (medium dose) or 232 mcg (high dose) via oral inhalation twice a day
Maximum Dose: 232 mcg twice a day

Fluticasone furoate INHALATION POWDER Arnuity Ellipta[R]):
Patients new to ICS: Initial dose: 100 mcg via oral inhalation once a day
-Patients previously receiving ICS as well as patients who have not adequately responded after 2 weeks may be titrated to a higher dose
Maximum dose: 200 mcg once a day

Comments:
-Higher initial doses may be considered in patients with poor asthma control or those who have previously required higher doses of other ICS.
-Inhaled short-acting beta(2)-agonists should be used for immediate relief if symptoms arise between doses.
-Maximum benefit of ICS may not be achieved for up to 2 weeks or longer; if adequate control is not achieved in 2 weeks, may increase dose without exceeding maximum dose.
-After asthma stability has been achieved, titrate to the lowest effective dose to reduce the possibility of side effects.
-Not indicated for the relief of acute bronchospasm.

Use: For the maintenance treatment of asthma as prophylactic therapy.

Fluticasone propionate 100 powder

fluticasone propionate 100 powder

Media:

fluticasone propionate 100 powderfluticasone propionate 100 powderfluticasone propionate 100 powderfluticasone propionate 100 powderfluticasone propionate 100 powder